Royce & Associates LP Sells 68,230 Shares of Harrow, Inc. (NASDAQ:HROW)

Royce & Associates LP trimmed its stake in Harrow, Inc. (NASDAQ:HROW) by 18.9% during the 4th quarter, HoldingsChannel reports. The fund owned 292,090 shares of the company’s stock after selling 68,230 shares during the quarter. Royce & Associates LP’s holdings in Harrow were worth $9,800,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. State Street Corp grew its holdings in shares of Harrow by 2.2% during the third quarter. State Street Corp now owns 730,973 shares of the company’s stock valued at $32,865,000 after buying an additional 15,554 shares during the last quarter. Geode Capital Management LLC boosted its stake in Harrow by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock valued at $32,500,000 after purchasing an additional 3,960 shares during the last quarter. Braidwell LP increased its holdings in shares of Harrow by 47.9% in the 3rd quarter. Braidwell LP now owns 439,638 shares of the company’s stock worth $19,766,000 after purchasing an additional 142,450 shares in the last quarter. First Turn Management LLC bought a new stake in shares of Harrow in the 3rd quarter worth $14,683,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Harrow by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company’s stock worth $8,563,000 after purchasing an additional 3,589 shares during the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on HROW. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Harrow in a report on Tuesday. B. Riley reduced their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th.

Harrow Stock Performance

Shares of HROW opened at $26.98 on Wednesday. The firm has a market capitalization of $960.89 million, a P/E ratio of -28.70 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a one year low of $9.30 and a one year high of $59.23. The business has a fifty day moving average of $30.01 and a 200 day moving average of $38.63.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.